Method of treating immune pathologies with low dose estrogen
The invention provides a method of ameliorating a Th1-mediated immune pathology in a mammal. The method is practiced by administering a low dose of estrogen to the mammal. Optionally, an immunotherapeutic agent can also be administered to the mammal. Also provided are kits containing a low dose of estrogen and an immunotherapeutic agent.
1. A method of ameliorating a Th1-mediated immune pathology in a human subject, comprising
administering a dose of estrogen to said human subject sufficient to raise the serum concentration of estrogen in said human to within the range from 30 pg/ml to 1000 pg/ml; and
administering a therapeutically effective amount of a glatiramer acetate to said human subject
thereby ameliorating the Th1-mediated immune pathology in said human subject, wherein the Th1-mediated immune pathology is multiple sclerosis.
2. The method of claim 1 , wherein said human subject is female.
3. The method of claim 1 , wherein said human subject is male.
4. The method of claim 1 , wherein said estrogen is selected from the group consisting of 17β-estradiol, estriol and estrone.
5. The method of claim 1 , wherein said estrogen is 17β-estradio 1 .
6. The method of claim 1 , wherein said estrogen is estriol.
7. The method of claim 1 , wherein said dose of estrogen is an amount sufficient to raise the serum concentration of estrogen in said human to within the range from 50 pg/ml to 500 pg/ml.
8. The method of claim 1 , wherein said dose of estrogen is an amount sufficient to raise the serum concentration of estrogen to within the range from 100 pg/ml to 250 pg/ml.
9. The method of claim 1 , wherein said estrogen is administered by a route selected from an oral, a transdermal, a respiratory, a subcutaneous and an intravenous route.
10. The method of claim 1 , wherein said amelioration is apparent by magnetic resonance imaging.
11. A method of ameliorating multiple sclerosis in a human subject, comprising
administering estriol to said human subject sufficient to raise the serum concentration of estriol in said human from 10 to 2,000 pg/ml and
administering a therapeutically effective amount of a glatiramer acetate, to said human subject
thereby ameliorating multiple sclerosis in said human subject.
12. The method of claim 11 , wherein said human subject is female.
13. The method of claim 11 , wherein said human subject is male.
14. The method of claim 11 , wherein said estriol is administered by a route selected from an oral, a transdermal, a respiratory, a subcutaneous and an intravenous route.
15. The method of claim 11 , wherein said amelioration is apparent by magnetic resonance imaging.
16. The method of claim 11 , comprising administering estriol to said human subject sufficient to raise the serum concentration of estriol in said human from 100 pg/ml to 2,000 pg/ml.